"Ozempic (Semaglutide) Reviewed by Dr. Reza Lankarani; including Comparison: Ozempic vs: Exercise/Diet vs. Bariatric Surgery"

"Ozempic (Semaglutide) Reviewed by Dr. Reza Lankarani; including Comparison: Ozempic vs: Exercise/Diet vs. Bariatric Surgery;ding the Comparison: Ozempic vs. Exercise"

 

Dr. Reza Lankarani’s article provides a structured comparison of Ozempic (semaglutide), lifestyle modifications, and bariatric surgery for weight management and type 2 diabetes mellitus (T2DM). The analysis is grounded in clinical evidence, citing trials such as the STEP 1 Trial and JAMA studies, which substantiate efficacy claims. Ozempic is positioned as a moderate-efficacy option (10–15% weight loss) with advantages in glycemic control but notable drawbacks, including high costs, gastrointestinal side effects, and dependency on prolonged use. Lifestyle interventions are framed as sustainable yet discipline-intensive, while bariatric surgery emerges as the most effective for severe obesity (25–35% weight loss) but carries surgical risks and irreversibility. The inclusion of formulary access, pricing, and insurance considerations enhances practical relevance for patients and clinicians. However, redundancies in comparison tables across pages and fragmented formatting detract from readability.  

The article’s limitations include superficial pharmacokinetic details (e.g., half-life mentioned but not contextualized) and reliance on rodent data for thyroid tumor risks without clarifying human applicability. While the author’s surgical expertise lends credibility to the bariatric surgery analysis, pharmacological nuances are underdeveloped. Notably, the discussion of Ozempic’s dual role in T2DM and obesity (via Wegovy) is thorough, and warnings about thyroid cancer and pregnancy are appropriately emphasized. A potential bias toward surgical solutions is mitigated by balanced pros-and-cons tables. Future iterations would benefit from streamlined content organization, expanded long-term outcome data, and deeper mechanistic insights. Overall, this review serves as a pragmatic primer for clinicians weighing therapeutic options, though structural and depth-related refinements could elevate its scholarly impact.

**References**  

1. Wilding JPH, et al. *STEP 1 Trial*. NEJM 2021 (semaglutide for obesity).  

2. Rubino F, et al. *Bariatric Surgery Outcomes*. JAMA 2020.  

3. American Diabetes Association. *Standards of Care in Diabetes*. 2023.  

4. Pi-Sunyer X, et al. *Lifestyle vs. Pharmacotherapy*. Diabetes Care 2022.

Tattoo ink exposure is associated with lymphoma and skin cancers – a Danish study of twins

"Tattoo ink exposure is associated with lymphoma and skin cancers – a Danish study of twins"

This Danish twin study investigated the association between tattoo ink exposure and cancer risk, utilizing a cohort (2,367 twins) and a case-cotwin design (316 twins). 

Results revealed elevated hazards of skin cancer (excluding basal cell carcinoma) and lymphoma among tattooed individuals, particularly with larger tattoos (> palm-sized): case-control analysis showed hazard ratios (HR) of 1.62 (95% CI: 1.08–2.41) for skin cancer and 2.73 (1.33–5.60) for lymphoma, while the cohort study reported higher HRs for skin cancer (3.91; 1.42–10.8) and basal cell carcinoma (2.83; 1.30–6.16). The twin-matched analysis, though limited by small sample sizes (e.g., 14 discordant pairs for skin cancer), found non-significant trends. 

The study posits that chronic inflammation from ink deposits or carcinogenic compounds (e.g., PAHs) may drive cancer risk, but acknowledges limitations like unmeasured confounders (e.g., sun exposure) and survivorship bias. 

Despite inconclusive causality, the findings underscore public health concerns given rising tattoo prevalence, urging further research into etiological pathways and preventive measures.

Clemmensen et al. https://lnkd.in/eCaNeTEC

BMC Public Health (2025) 25:170

بیوگرافی

بیوگرافی 

 جراح-پژوهشگر، دانشگاه علوم پزشکی ایران، تهران، ایران. 

 مقالات: 

  اثرات افزایشی اضطراب و اختلالات مصرف مواد را بر افکار خودکشی در میان بزرگسالان سیاه پوست در ایالات متحده.

 تفاوت های بین کشوری در ارتباط بین دیابت و ناتوانی. 

 تزریق مواد مخدر به نقاطی غیر از بازو: مطالعه انژکتورهای هروئین ایرانی. 

 تصحیح: تفاوت های بین کشوری در ارتباط بین دیابت و ناتوانی.

 داشتن شرکای جنسی متعدد در میان مصرف کنندگان ایرانی مواد مخدر تزریقی. 

 تجربیات: 

 کارآموزی، دانشگاه ایالتی نیویورک، جولای 2014- دسامبر 2014 (6 ماه).

 پژوهشگر فوق دکتری، دانشکده بهداشت عمومی دانشگاه میشیگان، فوریه 2013-ژانویه 2014 (1 سال).

 پژوهشگر فوق دکتری، مرکز پزشکی UCSF، آگوست 2013- سپتامبر 2013 (2 ماه)، منطقه خلیج سانفرانسیسکو.

 آبزرور، کلینیک مایو، سپتامبر 2012 - اکتبر 2012 (2 ماه)، جکسونویل، منطقه فلوریدا. 

 آبزرور، کلینیک مایو، می 2012 - ژوئیه 2012 (3 ماه)، جکسونویل، منطقه فلوریدا.

Biography

Biography

Surgeon-Researcher, Iran University of Medical Sciences, Tehran, Iran.

Publications:

* Ethnicity Modifies the Additive Effects of Anxiety and Drug Use Disorders on Suicidal Ideation among Black Adults in the United States.

* Cross-country Differences in the Association between Diabetes and Disability.

* Drug Injection to Sites Other Than the Arm: A Study of Iranian Heroin Injectors.

* Correction: Cross-country Differences in the Association between Diabetes and Disability.

* Having Multiple Sexual Partners among Iranian Injection Drug Users.

Experiences:

* Internship, The State University of New York, July 2014 – December 2014 (6 months).

* Postdoctoral Research Fellow, University of Michigan School of Public Health, February 2013 – January 2014 (1 year).

* Postdoctoral Research Fellow, UCSF Medical Center, August 2013 – September 2013 (2 months), San Francisco Bay Area.

* Observer, Mayo Clinic, September 2012 – October 2012 (2 months), Jacksonville, Florida Area.

* Observer, Mayo Clinic, May 2012 – July 2012 (3 months), Jacksonville, Florida Area.